Free Trial
NASDAQ:ENGN

enGene Q2 2025 Earnings Report

enGene logo
$3.68 +0.11 (+3.08%)
Closing price 08/8/2025 04:00 PM Eastern
Extended Trading
$3.76 +0.07 (+2.04%)
As of 08/8/2025 07:41 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

enGene EPS Results

Actual EPS
-$0.51
Consensus EPS
-$0.48
Beat/Miss
Missed by -$0.03
One Year Ago EPS
N/A

enGene Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

enGene Announcement Details

Quarter
Q2 2025
Time
Before Market Opens
Conference Call Date
Thursday, June 12, 2025
Conference Call Time
8:00AM ET

Upcoming Earnings

enGene's Q3 2025 earnings is scheduled for Wednesday, September 10, 2025, with a conference call scheduled on Tuesday, September 9, 2025 at 9:30 AM ET. Check back for transcripts, audio, and key financial metrics as they become available.

enGene Earnings Headlines

HIDDEN IN THE BOOK OF GENESIS…
“This land I will give to you…” — a 4,000-year-old line from Genesis may hold the key to unlocking a $150 trillion vault of untapped American wealth. Former CIA advisor Jim Rickards calls it the “Old Testament Wealth Code” — and says it could transform your financial future. He’s revealing everything in a new presentation.
See More enGene Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like enGene? Sign up for Earnings360's daily newsletter to receive timely earnings updates on enGene and other key companies, straight to your email.

About enGene

enGene (NASDAQ:ENGN), through its subsidiary enGene, Inc., operates as a clinical-stage biotechnology company that develops genetic medicines through the delivery of therapeutics to mucosal tissues and other organs. Its lead product candidate is EG-70 (detalimogene voraplasmid), which is a non-viral immunotherapy to treat non-muscle invasive bladder cancer patients with carcinoma-in-situ (Cis), who are unresponsive to treatment with Bacillus Calmette-Guérin. The company was founded in 2023 and is based in Saint-Laurent, Canada.

View enGene Profile

More Earnings Resources from MarketBeat